AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-20. Canceled
- 21. (previously presented) A compound of formula (II):

$$(R_2)_n$$
 R_1
 N
 $(R_3)_n$
 R_4
 (II)

or a pharmaceutically acceptable salt thereof, wherein:

A is $-N(O-C_1-C_6 \text{ alkyl})$ -, $-CH_2$ -, $-CH_2CH_2$ -, or -CH=CH-;

 R_1 is -halo, -CH₃, -NO₂, -CN, -OH, -OCH₃, -NH₂, -C(halo)₃, -CH(halo)₂, or -CH₂(halo);

each R₂ is independently:

(a) -halo, -CN, -OH, -NO₂, or -NH₂;

(b) $-(C_1-C_{10})$ alkyl, $-(C_2-C_{10})$ alkenyl, $-(C_2-C_{10})$ alkynyl, $-(C_3-C_{10})$

 C_{10})cycloalkyl, -(C_8 - C_{14})bicycloalkyl, -(C_8 - C_{14})tricycloalkyl, -(C_5 - C_{10})cycloalkenyl, -(C_8 - C_{14})bicycloalkenyl, -(C_8 - C_{14})tricycloalkenyl, -(C_8 - C_{10})cycloalkenyl, -(C_8 - C_{10}

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R₃ is independently:

(a) -halo, -CN, -OH, -NO₂, or -NH₂;

(b) $-(C_1-C_{10})$ alkyl, $-(C_2-C_{10})$ alkenyl, $-(C_2-C_{10})$ alkynyl, $-(C_3-C_{10})$

 C_{10})cycloalkyl, -(C_8 - C_{14})bicycloalkyl, -(C_8 - C_{14})tricycloalkyl, -(C_5 - C_{10})cycloalkenyl, -(C_8 - C_{14})bicycloalkenyl, -(C_8 - C_{14})tricycloalkenyl, -(C_8 - C_{14})tricycloalkyl, -(C_8 - C_{14})tricycloalkenyl, -(C_8 - $C_$

(c) -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

R₄ is:

(a) -(C_1 - C_{10})alkyl, -(C_2 - C_{10})alkenyl, -(C_2 - C_{10})alkynyl, -(C_3 - C_{10})cycloalkyl, -(C_8 - C_{14})tricycloalkyl, -(C_5 - C_{10})cycloalkenyl, -(C_8 - C_{14})tricycloalkenyl, -(C_8 - $C_$

(b) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_5 is independently -CN, -OH, -(C_1 - C_6)alkyl, -(C_2 - C_6)alkenyl, -halo, -N₃, -NO₂, -N(R_7)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)OR₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R_6 is independently -(C_1 - C_6)alkyl, -(C_2 - C_6)alkenyl, -(C_2 - C_6)alkynyl, -(C_3 - C_8)cycloalkyl, -(C_5 - C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -CN, -OH, -halo, -N₃, -NO₂, -N(R_7)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R_7 is independently -H, -(C_1 - C_6)alkyl, -(C_2 - C_6)alkenyl, -(C_2 - C_6)alkynyl, -(C_3 - C_8)cycloalkyl, -(C_5 - C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)₃, -CH(halo)₂ or -CH₂(halo);

each halo is independently -F, -Cl, -Br, or -I; n is an integer ranging from 0 to 2; and m is an integer ranging from 0 to 2.

22. (original) The compound of claim 21, wherein:

n is 0;

m is 0: and

R₄ is phenyl.

- 23. (original) The compound of claim 22, wherein the R₄ phenyl is unsubstituted.
- 24. (original) The compound of claim 22, wherein the R₄ phenyl is substituted at the 4-position.
- 25. (original) The compound of claim 24, wherein the R_4 phenyl is substituted with a -(C_1 - C_6) alkyl group.
- 26. (original) The compound of claim 25, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.
- 27. (original) The compound of claim 25, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.
- 28. (original) The compound of claim 24, wherein the R₄ phenyl is substituted with a -CF₃ group.
- 29. (original) The compound of claim 24, wherein the R₄ phenyl is substituted with a -OCF₃ group.
 - 30. (original) The compound of claim 21, wherein:

m is 1;

R₃ is methyl; and

R₄ is phenyl.

- 31. (original) The compound of claim 30, wherein the R₄ phenyl is unsubstituted.
- 32. (original) The compound of claim 30, wherein the R₄ phenyl is substituted at the 4-position.
- 33. (original) The compound of claim 32, wherein the R_4 phenyl is substituted with a -(C_1 - C_6) alkyl group.

- 34. (original) The compound of claim 33, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.
- 35. (original) The compound of claim 33, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.
- 36. (original) The compound of claim 32, wherein the R₄ phenyl is substituted with a -CF₃ group.
- 37. (original) The compound of claim 32, wherein the R₄ phenyl is substituted with a -OCF₃ group.
 - 38. (original) The compound of claim 21, wherein A is $-N(O-C_1-C_6 \text{ alkyl})$ -.
 - 39. (original) The compound of claim 21, wherein A is -CH₂-.
 - 40. (original) The compound of claim 21, wherein A is -CH₂CH₂-.
 - 41. (original) The compound of claim 21, wherein A is -CH=CH-.

42-61. Canceled

62. (original) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21 and a pharmaceutically acceptable carrier or excipient.

63-85. Canceled

- 86. (original) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 21 and a pharmaceutically acceptable carrier or excipient.
 - 87. Canceled

88. (previously presented) A compound of formula (IV):

or a pharmaceutically acceptable salt thereof, wherein:

Ar₂ is

$$(R_9)_s$$

$$(R_9)_s$$

$$(R_{11})_q$$

$$(R_{11})_q$$

$$(R_{11})_q$$

$$(R_{11})_q$$

 $R_1 \ is \ -H, \ -halo, \ -CH_3, \ -NO_2, \ -CN, \ -OH, \ -OCH_3, \ -NH_2, \ -C(halo)_3, \ -CH(halo)_2,$ or $-CH_2(halo)$;

each R₂ is independently:

(a) -halo, -CN, -OH, -NO2, or -NH2;

(b) -(C_1 - C_{10})alkyl, -(C_2 - C_{10})alkenyl, -(C_2 - C_{10})alkynyl, -(C_3 - C_{10})cycloalkyl, -(C_8 - C_{14})bicycloalkyl, -(C_8 - C_{14})tricycloalkyl, -(C_5 - C_{10})cycloalkenyl, -(C_8 - C_{14})bicycloalkenyl, -(C_8 - C_{14})tricycloalkenyl, -(C_8 - C_8

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R₃ is independently:

(a) -halo, -CN, -OH, -NO₂, or -NH₂;

(b) $-(C_1-C_{10})$ alkyl, $-(C_2-C_{10})$ alkenyl, $-(C_2-C_{10})$ alkynyl, $-(C_3-C_{10})$

 C_{10})cycloalkyl, -(C_8 - C_{14})bicycloalkyl, -(C_8 - C_{14})tricycloalkyl, -(C_5 - C_{10})cycloalkenyl, -(C_8 - C_{14})bicycloalkenyl, -(C_8 - C_{14})tricycloalkenyl, -(C_8 - C_{10})cycloalkenyl, -(C_8 - C_8 -

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_5 is independently -CN, -OH, -(C_1 - C_6)alkyl, -(C_2 - C_6)alkenyl, -(C_2 - C_6)alkynyl, -halo, -N₃, -NO₂, -N(R_7)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)OR₇, -S(O)R₇, or -S(O)₂R₇;

each R_6 is independently -(C_1 - C_6)alkyl, -(C_2 - C_6)alkenyl, -(C_2 - C_6)alkynyl, -(C_3 - C_8)cycloalkyl, -(C_5 - C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -CN, -OH, -halo, -N₃, -NO₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R_7 is independently -H, -(C_1 - C_6)alkyl, -(C_2 - C_6)alkenyl, -(C_2 - C_6)alkynyl, -(C_3 - C_8)cycloalkyl, -(C_5 - C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)₃, -CH(halo)₂, or -CH₂(halo);

each R_8 is independently -(C_1 - C_6)alkyl, -(C_2 - C_6)alkenyl, -(C_2 - C_6)alkynyl, -(C_3 - C_8)cycloalkyl, -(C_5 - C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)₃, -CH(halo)₂, or -CH₂(halo);

each R_9 is independently -(C_1 - C_6)alkyl, -(C_2 - C_6)alkenyl, -(C_2 - C_6)alkynyl, -(C_3 - C_8)cycloalkyl, -(C_5 - C_8)cycloalkenyl, -phenyl, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -CN, -OH, -halo, -N₃, -NO₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)OR₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R_{11} is independently -CN, -OH, -(C_1 -C₆)alkyl, -(C_2 -C₆)alkenyl, -(C_2 -C₆)alkynyl, -halo, -N₃, -NO₂, -N(R_7)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇; each halo is independently -F, -Cl, -Br, or -I; n is an integer ranging from 0 to 2; m is 0 or 1; o is an integer ranging from 0 to 4; q is an integer ranging from 0 to 6; r is an integer ranging from 0 to 5; s is an integer ranging from 0 to 4; and t is an integer ranging from 0 to 2.

89. (previously presented) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 88 and a pharmaceutically acceptable carrier or excipient.

90-98. Canceled

- 99. (previously presented) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 88 and a pharmaceutically acceptable carrier or excipient.
 - 100. (previously presented) A compound of formula (V):

(V)

or a pharmaceutically acceptable salt thereof, wherein:

Ar₂ is

$$(R_9)_s$$

$$(R_9)_s$$

$$(R_9)_s$$

$$(R_11)_q$$

$$(R_{11})_q$$

$$(R_{11})_q$$

$$(R_{11})_q$$

$$(R_{11})_q$$

$$(R_{11})_q$$

$$(R_{11})_q$$

 R_1 is -H, -halo, -CH₃, -NO₂, -CN, -OH, -OCH₃, -NH₂, -C(halo)₃, -CH(halo)₂, or -CH₂(halo);

each R₂ is independently:

(a) -halo, -CN, -OH, -NO₂, or -NH₂;

(b) $-(C_1-C_{10})$ alkyl, $-(C_2-C_{10})$ alkenyl, $-(C_2-C_{10})$ alkynyl, $-(C_3-C_{10})$

 C_{10})cycloalkyl, -(C_8 - C_{14})bicycloalkyl, -(C_8 - C_{14})tricycloalkyl, -(C_5 - C_{10})cycloalkenyl, -(C_8 - C_{14})bicycloalkenyl, -(C_8 - C_{14})tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R₃ is independently:

(a) -halo, -CN, -OH, -NO₂, or -NH₂;

(b) $-(C_1-C_{10})$ alkyl, $-(C_2-C_{10})$ alkenyl, $-(C_2-C_{10})$ alkynyl, $-(C_3-C_{10})$

 C_{10})cycloalkyl, -(C_8 - C_{14})bicycloalkyl, -(C_8 - C_{14})tricycloalkyl, -(C_5 - C_{10})cycloalkenyl, -(C_8 - C_{14})tricycloalkenyl, -(C_8 - C_8 -C

```
membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more
R<sub>5</sub> groups; or
                                   (c) -phenyl, -naphthyl, -(C<sub>14</sub>)aryl or -(5- to 10-membered)heteroaryl,
each of which is unsubstituted or substituted with one or more R<sub>6</sub> groups;
                       each R<sub>5</sub> is independently -CN, -OH, -(C<sub>1</sub>-C<sub>6</sub>)alkyl, -(C<sub>2</sub>-C<sub>6</sub>)alkenyl, -(C<sub>2</sub>-
C<sub>6</sub>)alkynyl, -halo, -N<sub>3</sub>, -NO<sub>2</sub>, -N(R<sub>7</sub>)<sub>2</sub>, -CH=NR<sub>7</sub>, -NR<sub>7</sub>OH, -OR<sub>7</sub>, -COR<sub>7</sub>, -C(O)OR<sub>7</sub>,
-OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -S(O)_2R_7;
                       each R<sub>6</sub> is independently -(C<sub>1</sub>-C<sub>6</sub>)alkyl, -(C<sub>2</sub>-C<sub>6</sub>)alkenyl, -(C<sub>2</sub>-C<sub>6</sub>)alkynyl, -(C<sub>3</sub>-
C<sub>8</sub>)cycloalkyl, -(C<sub>5</sub>-C<sub>8</sub>)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)<sub>3</sub>,
-CH(halo)<sub>2</sub>, -CH<sub>2</sub>(halo), -CN, -OH, -halo, -N<sub>3</sub>, -NO<sub>2</sub>, -CH=NR<sub>7</sub>, -NR<sub>7</sub>OH, -OR<sub>7</sub>, -COR<sub>7</sub>,
-C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -S(O)_2R_7;
                       each R<sub>7</sub> is independently -H, -(C<sub>1</sub>-C<sub>6</sub>)alkyl, -(C<sub>2</sub>-C<sub>6</sub>)alkenyl, -(C<sub>2</sub>-C<sub>6</sub>)alkynyl,
-(C<sub>3</sub>-C<sub>8</sub>)cycloalkyl, -(C<sub>5</sub>-C<sub>8</sub>)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle,
-C(halo)<sub>3</sub>, -CH(halo)<sub>2</sub>, or -CH<sub>2</sub>(halo);
                       each R<sub>8</sub> is independently -(C<sub>1</sub>-C<sub>6</sub>)alkyl, -(C<sub>2</sub>-C<sub>6</sub>)alkenyl, -(C<sub>2</sub>-C<sub>6</sub>)alkynyl, -(C<sub>3</sub>-
C<sub>8</sub>)cycloalkyl, -(C<sub>5</sub>-C<sub>8</sub>)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)<sub>3</sub>,
-CH(halo)<sub>2</sub>, or -CH<sub>2</sub>(halo);
                        each R<sub>9</sub> is independently -(C<sub>1</sub>-C<sub>6</sub>)alkyl, -(C<sub>2</sub>-C<sub>6</sub>)alkenyl, -(C<sub>2</sub>-C<sub>6</sub>)alkynyl, -(C<sub>3</sub>
C<sub>8</sub>)cycloalkyl, -(C<sub>5</sub>-C<sub>8</sub>)cycloalkenyl, -phenyl, -C(halo)<sub>3</sub>, -CH(halo)<sub>2</sub>, -CH<sub>2</sub>(halo), -CN, -OH,
-halo, -N<sub>3</sub>, -NO<sub>2</sub>, -CH=NR<sub>7</sub>, -NR<sub>7</sub>OH, -OR<sub>7</sub>, -COR<sub>7</sub>, -C(O)OR<sub>7</sub>, -OC(O)OR<sub>7</sub>,
-SR_7, -S(O)R_7, or -S(O)_2R_7;
                        each R<sub>11</sub> is independently -CN, -OH, -(C<sub>1</sub>-C<sub>6</sub>)alkyl, -(C<sub>2</sub>-C<sub>6</sub>)alkenyl, -(C<sub>2</sub>-
C<sub>6</sub>)alkynyl, -halo, -N<sub>3</sub>, -NO<sub>2</sub>, -N(R<sub>7</sub>)<sub>2</sub>, -CH=NR<sub>7</sub>, -NR<sub>7</sub>OH, -OR<sub>7</sub>, -COR<sub>7</sub>, -C(O)OR<sub>7</sub>,
-OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, or -S(O)_2R_7;
                        each halo is independently -F, -Cl, -Br, or -I;
                        n is an integer ranging from 0 to 2;
                        m is 0 or 1;
                        o is an integer ranging from 0 to 4;
                        q is an integer ranging from 0 to 6;
                        r is an integer ranging from 0 to 5;
                        s is an integer ranging from 0 to 4; and
```

t is an integer ranging from 0 to 2.

101. (previously presented) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 100 and a pharmaceutically acceptable carrier or excipient.

102-110. Canceled

- 111. (previously presented) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 100 and a pharmaceutically acceptable carrier or excipient.
 - 112. (currently amended) The A compound of formula (I) elaim 1, wherein:

$$(R_2)_n$$
 $(R_3)_m$
 (I)

or a pharmaceutically acceptable salt thereof, wherein:

A is -NH-, $-N(C_1-C_6)$ alkyl-, or -N-(O- C_1 - C_6 alkyl)-;

n is 0;

m is 1;

 R_3 is -CH₃;

R₁ is -halo; and

R₄ is phenyl which is unsubstituted or substituted with one or more R₆

groups;

 $\frac{\text{each }R_6 \text{ is independently -}(C_1\text{-}C_6)\text{alkyl, -}(C_2\text{-}C_6)\text{alkenyl, -}(C_2\text{-}C_6)\text{alkynyl,}}{-(C_3\text{-}C_8)\text{cycloalkyl, -}(C_5\text{-}C_8)\text{cycloalkenyl, -}\text{phenyl, -}(3\text{- to 5-membered})\text{heterocycle,}}\\ -C(\text{halo})_3, -CH(\text{halo})_2, -CH_2(\text{halo}), -CN, -OH, -\text{halo, -N}_3, -NO_2, -N(R_7)_2, -CH=NR_7,}\\ -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)R_7, -OC(O)OR_7, -SR_7, -S(O)R_7, \text{ or -S}(O)_2R_7;}$

each R_7 is independently -H, -(C_1 - C_6)alkyl, -(C_2 - C_6)alkenyl, -(C_2 - C_6)alkynyl, -(C_3 - C_8)cycloalkyl, -(C_5 - C_8)cycloalkenyl, -phenyl, -(3- to 5membered)heterocycle, -C(halo)₃, -CH(halo)₂, or -CH₂(halo); and each halo is independently -F, -Cl, -Br, or -I.

- 113. (original) The compound of claim 112, wherein the R₄ phenyl is unsubstituted.
- 114. (original) The compound of claim 112, wherein the R₄ phenyl is substituted at the 4-position.
- 115. (original) The compound of claim 114, wherein the R_4 phenyl is substituted with a -(C_1 - C_6) alkyl group.
- 116. (original) The compound of claim 115, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.
- 117. (original) The compound of claim 115, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.
- 118. (previously presented) The compound of claim 114, wherein the R_4 phenyl is substituted with a -CF₃ group.
- 119. (previously presented) The compound of claim 114, wherein the R_4 phenyl is substituted with a -OCF₃ group.
 - 120. (original) The compound of claim 112, wherein R_1 is -Cl.
- 121. (original) The compound of claim 120, wherein the R₄ phenyl is unsubstituted.
- 122. (original) The compound of claim 120, wherein the R₄ phenyl is substituted at the 4-position.

- 123. (original) The compound of claim 122, wherein the R_4 phenyl is substituted with a -(C_1 - C_6) alkyl group.
- 124. (original) The compound of claim 123, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.
- 125. (original) The compound of claim 123, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.
- 126. (previously presented) The compound of claim 122, wherein the R_4 phenyl is substituted with a -CF₃ group.
- 127. (previously presented) The compound of claim 122, wherein the R_4 phenyl is substituted with a -OCF₃ group.
 - 128. (original) The compound of claim 112, wherein R_1 is -F.
- 129. (original) The compound of claim 128, wherein the R_4 phenyl is unsubstituted.
- 130. (original) The compound of claim 128, wherein the R₄ phenyl is substituted at the 4-position.
- 131. (original) The compound of claim 130, wherein the R_4 phenyl is substituted with a $-(C_1-C_6)$ alkyl group.
- 132. (original) The compound of claim 131, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.
- 133. (original) The compound of claim 131, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.
- 134. (previously presented) The compound of claim 130, wherein the R₄ phenyl is substituted with a -CF₃ group.

- 135. (previously presented) The compound of claim 130, wherein the R_4 phenyl is substituted with a -OCF₃ group.
 - 136. (currently amended) The A compound of formula (I) elaim 1, wherein:

$$\begin{array}{c|c}
(R_2)_n & & \\
N & & \\
N & & \\
N & & \\
(R_3)_m & \\
\hline
(I)
\end{array}$$

or a pharmaceutically acceptable salt thereof, wherein:

A is -NH-, $-N(C_1-C_6)$ alkyl-, or $-N-(O-C_1-C_6)$ alkyl)-;

n is 0;

m is 1;

 R_3 is -CH₃;

R₁ is -CH₃; and

R₄ is phenyl which is unsubstituted or substituted with one or more R₆

groups;

each R_6 is independently -(C_1 - C_6)alkyl, -(C_2 - C_6)alkenyl, -(C_2 - C_6)alkynyl, -(C_3 - C_8)cycloalkyl, -(C_5 - C_8)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, - $C(halo)_3$, - $CH(halo)_2$, - $CH_2(halo)$, -CN, -OH, -halo, - N_3 , - NO_2 , - $N(R_7)_2$, -CH= NR_7 , - NR_7OH , - OR_7 , - COR_7 , - $C(O)OR_7$, - $OC(O)OR_7$, - $OC(O)OR_7$, - SR_7 , - $S(O)R_7$, or - $S(O)_2R_7$; each R_7 is independently -H, -(C_1 - C_6)alkyl, -(C_2 - C_6)alkenyl, -(C_2 -

C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)₃, -CH(halo)₂, or -CH₂(halo); and each halo is independently -F, -Cl, -Br, or -I.

137. (original) The compound of claim 136, wherein the R₄ phenyl is unsubstituted.

- 138. (original) The compound of claim 136, wherein the R₄ phenyl is substituted at the 4-position.
- 139. (original) The compound of claim 138, wherein the R_4 phenyl is substituted with a -(C_1 - C_6) alkyl group.
- 140. (original) The compound of claim 139, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.
- 141. (original) The compound of claim 139, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.
- 142. (previously presented) The compound of claim 138, wherein the R_4 phenyl is substituted with a -CF₃ group.
- 143. (previously presented) The compound of claim 138, wherein the R₄ phenyl is substituted with a -OCF₃ group.
 - 144. (original) The compound of claim 21, wherein:

m is 1;

 R_3 is -CH₃;

R₁ is -halo; and

R₄ is phenyl.

- 145. (original) The compound of claim 144, wherein the R₄ phenyl is unsubstituted.
- 146. (original) The compound of claim 144, wherein the R₄ phenyl is substituted at the 4-position.
- 147. (original) The compound of claim 146, wherein the R_4 phenyl is substituted with a -(C_1 - C_6) alkyl group.

- 148. (original) The compound of claim 147, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.
- 149. (original) The compound of claim 147, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.
- 150. (previously presented) The compound of claim 146, wherein the R_4 phenyl is substituted with a -CF₃ group.
- 151. (previously presented) The compound of claim 146, wherein the R₄ phenyl is substituted with a -OCF₃ group.
 - 152. (original) The compound of claim 144, wherein R_1 is -Cl.
- 153. (original) The compound of claim 152, wherein the R₄ phenyl is unsubstituted.
- 154. (original) The compound of claim 152, wherein the R₄ phenyl is substituted at the 4-position.
- 155. (original) The compound of claim 154, wherein the R_4 phenyl is substituted with a $-(C_1-C_6)$ alkyl group.
- 156. (original) The compound of claim 155, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.
- 157. (original) The compound of claim 155, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.
- 158. (previously presented) The compound of claim 154, wherein the R_4 phenyl is substituted with a -CF₃ group.
- 159. (previously presented) The compound of claim 154, wherein the R₄ phenyl is substituted with a -OCF₃ group.

- 160. (original) The compound of claim 144, wherein R_1 is -F.
- 161. (original) The compound of claim 160, wherein the R₄ phenyl is unsubstituted.
- 162. (original) The compound of claim 160, wherein the R₄ phenyl is substituted at the 4-position.
- 163. (original) The compound of claim 162, wherein the R_4 phenyl is substituted with a -(C_1 - C_6) alkyl group.
- 164. (original) The compound of claim 163, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.
- 165. (original) The compound of claim 163, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.
- 166. (previously presented) The compound of claim 162, wherein the R₄ phenyl is substituted with a -CF₃ group.
- 167. (previously presented) The compound of claim 162, wherein the R₄ phenyl is substituted with a -OCF₃ group.
 - 168. (original) The compound of claim 21, wherein:

m is 1;

R₁ is -CH₃; and

R₄ is phenyl.

- 169. (original) The compound of claim 168, wherein the R₄ phenyl is unsubstituted.
- 170. (original) The compound of claim 168, wherein the R₄ phenyl is substituted at the 4-position.

- 171. (original) The compound of claim 170, wherein the R_4 phenyl is substituted with a -(C_1 - C_6) alkyl group.
- 172. (original) The compound of claim 171, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.
- 173. (original) The compound of claim 171, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.
- 174. (previously presented) The compound of claim 170, wherein the R₄ phenyl is substituted with a -CF₃ group.
- 175. (previously presented) The compound of claim 170, wherein the R₄ phenyl is substituted with a -OCF₃ group.
 - 176. (currently amended) The A compound of formula (III) elaim 1, wherein:

or a pharmaceutically acceptable salt thereof, wherein:

A is -NH- or -N(C_1 - C_6)alkyl-;

n is 0;

m is 1;

R₃ is -CH₃;

R₁ is -halo; and

R₄ is phenyl which is unsubstituted or substituted with one or more R₆

groups;

 $\frac{\text{each }R_6 \text{ is independently -}(C_1\text{-}C_6)\text{alkyl, -}(C_2\text{-}C_6)\text{alkenyl, -}(C_2\text{-}C_6)\text{alkynyl,}}{-(C_3\text{-}C_8)\text{cycloalkyl, -}(C_5\text{-}C_8)\text{cycloalkenyl, -phenyl, -}(3\text{- to 5-membered})\text{heterocycle,}}{-C(\text{halo})_3, -\text{CH}(\text{halo})_2, -\text{CH}_2(\text{halo}), -\text{CN, -OH, -halo, -N}_3, -\text{NO}_2, -\text{N}(R_7)_2, -\text{CH}=\text{NR}_7,}\\ -\text{NR}_7\text{OH, -OR}_7, -\text{COR}_7, -\text{C}(\text{O})\text{OR}_7, -\text{OC}(\text{O})\text{R}_7, -\text{OC}(\text{O})\text{OR}_7, -\text{SR}_7, -\text{S}(\text{O})\text{R}_7, \text{ or -S}(\text{O})_2\text{R}_7;}\\ -\text{each }R_7 \text{ is independently -H, -}(C_1\text{-}C_6)\text{alkyl, -}(C_2\text{-}C_6)\text{alkenyl, -}(C_2\text{-}C_6)\text{alkenyl, -}(C_2\text{-}C_6)\text{alkynyl, -}(C_3\text{-}C_8)\text{cycloalkyl, -}(C_5\text{-}C_8)\text{cycloalkenyl, -phenyl, -}(3\text{- to 5-membered})\text{heterocycle, -C}(\text{halo})_3, -\text{CH}(\text{halo})_2, \text{ or -CH}_2(\text{halo}); \text{ and each halo is independently -F, -Cl, -Br, or -I}.}$

- 177. (original) The compound of claim 176, wherein the R₄ phenyl is unsubstituted.
- 178. (original) The compound of claim 176, wherein the R₄ phenyl is substituted at the 4-position.
- 179. (original) The compound of claim 178, wherein the R_4 phenyl is substituted with a -(C_1 - C_6) alkyl group.
- 180. (original) The compound of claim 179, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.
- 181. (original) The compound of claim 179, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.
- 182. (previously presented) The compound of claim 178, wherein the R_4 phenyl is substituted with a -CF₃ group.
- 183. (previously presented) The compound of claim 178, wherein the R₄ phenyl is substituted with a -OCF₃ group.
 - 184. (original) The compound of claim 176, wherein R_1 is -Cl.
- 185. (original) The compound of claim 184, wherein the R₄ phenyl is unsubstituted.

- 186. (original) The compound of claim 184, wherein the R₄ phenyl is substituted at the 4-position.
- 187. (original) The compound of claim 186, wherein the R_4 phenyl is substituted with a $-(C_1-C_6)$ alkyl group.
- 188. (original) The compound of claim 187, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.
- 189. (original) The compound of claim 187, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.
- 190. (previously presented) The compound of claim 186, wherein the R₄ phenyl is substituted with a -CF₃ group.
- 191. (previously presented) The compound of claim 186, wherein the R₄ phenyl is substituted with a -OCF₃ group.
 - 192. (original) The compound of claim 176, wherein R_1 is -F.
- 193. (original) The compound of claim 192, wherein the R₄ phenyl is unsubstituted.
- 194. (original) The compound of claim 192, wherein the R₄ phenyl is substituted at the 4-position.
- 195. (original) The compound of claim 194, wherein the R_4 phenyl is substituted with a -(C_1 - C_6) alkyl group.
- 196. (original) The compound of claim 195, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.
- 197. (original) The compound of claim 195, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.

- 198. (previously presented) The compound of claim 194, wherein the R_4 phenyl is substituted with a -CF₃ group.
- 199. (previously presented) The compound of claim 194, wherein the R₄ phenyl is substituted with a -OCF₃ group.
 - 200. (currently amended) The A compound of formula (III) elaim 1, wherein:

<u>(III)</u>

or a pharmaceutically acceptable salt thereof, wherein:

A is -NH- or -N(C_1 - C_6)alkyl-;

n is 0;

m is 1;

 R_3 is -CH₃;

R₁ is -CH₃; and

 R_4 is phenyl which is unsubstituted or substituted with one or more R_6

groups;

 $\frac{\text{each }R_6 \text{ is independently -}(C_1\text{-}C_6)\text{alkyl, -}(C_2\text{-}C_6)\text{alkenyl, -}(C_2\text{-}C_6)\text{alkynyl,}}{-(C_3\text{-}C_8)\text{cycloalkyl, -}(C_5\text{-}C_8)\text{cycloalkenyl, -phenyl, -}(3\text{- to 5-membered})\text{heterocycle,}}\\ -C(\text{halo})_3, -CH(\text{halo})_2, -CH_2(\text{halo}), -CN, -OH, -\text{halo, -N}_3, -NO_2, -N(R_7)_2, -CH=NR_7,}\\ -NR_7OH, -OR_7, -COR_7, -C(O)OR_7, -OC(O)OR_7, -OC(O)OR_7, -SR_7, -S(O)R_7, \text{ or -S}(O)_2R_7;}$

each R₇ is independently -H, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-

 $\underline{C_6}$ alkynyl, -($\underline{C_3}$ - $\underline{C_8}$) cycloalkyl, -($\underline{C_5}$ - $\underline{C_8}$) cycloalkenyl, -phenyl, -(3- to 5-

membered)heterocycle, -C(halo)3, -CH(halo)2, or -CH2(halo); and

each halo is independently -F, -Cl, -Br, or -I.

- 201. (original) The compound of claim 200, wherein the R₄ phenyl is unsubstituted.
- 202. (original) The compound of claim 200, wherein the R₄ phenyl is substituted at the 4-position.
- 203. (original) The compound of claim 202, wherein the R_4 phenyl is substituted with a -(C_1 - C_6) alkyl group.
- 204. (original) The compound of claim 203, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.
- 205. (original) The compound of claim 203, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.
- 206. (previously presented) The compound of claim 202, wherein the R₄ phenyl is substituted with a -CF₃ group.
- 207. (previously presented) The compound of claim 202, wherein the R_4 phenyl is substituted with a -OCF₃ group.
- 208. (new) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 112 and a pharmaceutically acceptable carrier or excipient.
- 209. (new) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 112 and a pharmaceutically acceptable carrier or excipient.
- 210. (new) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 136 and a pharmaceutically acceptable carrier or excipient.

- 211. (new) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 136 and a pharmaceutically acceptable carrier or excipient.
- 212. (new) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 176 and a pharmaceutically acceptable carrier or excipient.
- 213. (new) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 176 and a pharmaceutically acceptable carrier or excipient.
- 214. (new) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 200 and a pharmaceutically acceptable carrier or excipient.
- 215. (new) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 200 and a pharmaceutically acceptable carrier or excipient.
 - 216. (new) The compound of claim 88, wherein:

t is 0;

m is 0; and

Ar₂ is phenyl.

- 217. (new) The compound of claim 216, wherein the Ar₂ phenyl is unsubstituted.
- 218. (new) The compound of claim 216, wherein the Ar_2 phenyl is substituted at the 4-position.
- 219. (new) The compound of claim 218, wherein the Ar_2 phenyl is substituted with a -(C_1 - C_6) alkyl group.

- 220. (new) The compound of claim 219, wherein the -(C₁-C₆) alkyl group is a *tert*-butyl group.
- 221. (new) The compound of claim 219, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.
- 222. (new) The compound of claim 218, wherein the Ar₂ phenyl is substituted with a -CF₃ group.
- 223. (new) The compound of claim 218, wherein the Ar₂ phenyl is substituted with a -OCF₃ group.
 - 224. (new) The compound of claim 88, wherein:

t is 0;

m is 1;

R₃ is methyl; and

Ar₂ is phenyl.

- 225. (new) The compound of claim 224, wherein the Ar₂ phenyl is unsubstituted.
- 226. (new) The compound of claim 224, wherein the Ar_2 phenyl is substituted at the 4-position.
- 227. (new) The compound of claim 226, wherein the Ar_2 phenyl is substituted with a -(C_1 - C_6) alkyl group.
- 228. (new) The compound of claim 227, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.
- 229. (new) The compound of claim 227, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.
- 230. (new) The compound of claim 226, wherein the Ar₂ phenyl is substituted with a -CF₃ group.

- 231. (new) The compound of claim 226, wherein the Ar₂ phenyl is substituted with a -OCF₃ group.
 - 232. (new) The compound of claim 100, wherein:

t is 0;

m is 0; and

Ar₂ is phenyl.

- 233. (new) The compound of claim 232, wherein the Ar₂ phenyl is unsubstituted.
- 234. (new) The compound of claim 232, wherein the Ar_2 phenyl is substituted at the 4-position.
- 235. (new) The compound of claim 234, wherein the Ar_2 phenyl is substituted with a -(C_1 - C_6) alkyl group.
- 236. (new) The compound of claim 235, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.
- 237. (new) The compound of claim 235, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.
- 238. (new) The compound of claim 234, wherein the Ar_2 phenyl is substituted with a -CF₃ group.
- 239. (new) The compound of claim 234, wherein the Ar₂ phenyl is substituted with a -OCF₃ group.
 - 240. (new) The compound of claim 100, wherein:

n is 0;

t is 0;

m is 1;

R₃ is methyl; and

Ar₂ is phenyl.

- 241. (new) The compound of claim 240, wherein the Ar₂ phenyl is unsubstituted.
- 242. (new) The compound of claim 240, wherein the Ar_2 phenyl is substituted at the 4-position.
- 243. (new) The compound of claim 242, wherein the Ar_2 phenyl is substituted with a -(C_1 - C_6) alkyl group.
- 244. (new) The compound of claim 243, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.
- 245. (new) The compound of claim 243, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.
- 246. (new) The compound of claim 242, wherein the Ar₂ phenyl is substituted with a -CF₃ group.
- 247. (new) The compound of claim 242, wherein the Ar₂ phenyl is substituted with a -OCF₃ group.

jn 🐷